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We sought to identify predictors of the decline in renal
function, especially those that are modifiable, in the 5488
participants of the prospective, community-based cohort
study PREVEND who completed three visits during a mean
follow-up of 6.5 years. The change in renal function was
used as the outcome and this was calculated as the linear
regression of three estimated GFR measurements obtained
during follow-up. Risk factors, known to influence renal
outcome in patients with primary renal diseases, were used
as potential predictors in multivariate regression analyses.
High systolic blood pressure and plasma glucose were found
to be independent predictors for an accelerated decline in
function for both genders. In males, albuminuria was the
strongest independent predictor for renal function decline,
whereas in females albuminuria was univariately associated
only after adjustment for age. The direction of the association
between cholesterol/HDL ratio and decline of renal function
differed by gender. Surprisingly, in males, waist
circumference was an independent predictor and positively
associated with renal function outcome. These studies show
that there are gender differences in the standard predictors
of the decline in renal function.
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Chronic kidney disease (CKD) is a growing public health
problem worldwide.1 In 2000, approximately 300,000
patients had end-stage renal disease (ESRD) in the United
States alone, and this number is expected to double by the
year 2010.2 Furthermore, the earlier stages of CKD are
expected to be about 80 times more prevalent.3 Given these
expectations, it is evidently important to identify risk factors
of renal function decline. Such factors can be implemented in
screening programs to identify subjects at high risk of renal
function decline, who may benefit from early preventive
treatment.
Most studies that have been performed on this topic have
reported on predictors of the development of CKD
(estimated glomerular filtration rate (eGFR) o60 ml/min/
1.73 m2) or ESRD. However, the adverse consequences of
renal insufficiency appear not to be limited to those whose
renal function falls below a certain threshold. For instance,
even subjects with relatively minor impairment of renal
function are already at increased risk of cardiovascular
disease.4–8 The Hoorn study, a prospective population-based
study including subjects with an eGFR ranging from 17 to
117 ml/min/1.73 m2 reported that a 5 ml/min/1.73 m2 lower
eGFR was associated with a 26% increase in the risk of
cardiovascular death over the entire range of baseline renal
function.4 Therefore, we aimed to investigate predictors of
renal function decline, especially modifiable ones, in subjects
over a broad eGFR range. For this analysis, we used data of
subjects who participated in a community-based prospective
cohort study. As outcome variable we calculated for each
participant the slope through three eGFR values over time.
Multivariate regression analysis was applied to identify
variables that were associated with renal function decline.
RESULTS
Mean follow-up of the 5488 subjects in this analysis was 6.5
years (35,500 person-years of follow-up). Baseline charac-
teristics of the overall study population are given in Table 1.
Of note, the results of multivariate linear regression analyses
showed that gender was a strong effect modifier, because
a significant interaction term was found between urinary
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albumin excretion (UAE) and gender (Po0.001), and
between cholesterol/high-density lipoprotein (HDL) ratio
and gender (P¼ 0.005) versus the change in eGFR over time.
The statistical significance of these interaction terms indicate
that the association between UAE versus outcome and
cholesterol/HDL ratio versus outcome is not similar in males
and females. Therefore, we stratified all further analyses by
gender. Consequently, Table 1 shows also baseline character-
istics for males (n¼ 2770) and females (n¼ 2718) separately.
At baseline, males had a significantly higher waist circum-
ference, systolic blood pressure, percentage ACEi/A2A
treatment, cholesterol/HDL ratio, percentage lipid lowering
treatment, triglycerides, plasma glucose, and a higher UAE,
urea, and sodium excretion and also a higher eGFR. For
males, the range of UAE is 1.18–2960 mg/24 h and for females
it is 1.0–3610 mg/24 h. For males, the eGFR values are
between 23.2 and 155.9 ml/min/1.73 m2 and for females the
values are between 21.9 and 136.3 ml/min/1.73 m2. The mean
eGFR slope over time in males was 0.55±1.47 ml/min/
1.73 m2/year, and in females it was 0.33±1.41 ml/min/
1.73 m2/year (Po0.001 for males versus females). The
mean serum creatinine levels during the three screening
rounds were 83.6±14.4, 84.9±19.0, and 85.1±22.9 mmol/l,
respectively.
Table 2 shows the results of the univariate linear regression
analyses, and Table 3 shows the effect of correction for age
and baseline eGFR. In both males and females, systolic blood
pressure, plasma glucose, and UAE were significantly and
negatively associated with slope of renal function, indicating
that a higher systolic blood pressure, plasma glucose and
UAE were associated with a larger decline in eGFR. Other
variables were only associated with renal function decline in
one of the genders. For instance, Ln CRP was only associated
with renal function decline in females. Surprisingly, some
variables were associated differently in the two genders: in
males, lower waist circumference and a lower cholesterol/
HDL ratio predicted accelerated renal function decline,
whereas in females an opposite association was found.
Tables 4 and 5 present the results of the gender-specific
multivariate linear regression models. A higher (absolute)
standardized beta value indicates a stronger association
between the independent variable and the outcome change
in eGFR over time. In males, a higher systolic blood pressure,
plasma glucose, and UAE were associated with more renal
function decline. In contrast, a higher waist circumference
and cholesterol/HDL ratio were associated with less renal
function decline over time. The quadratic terms of UAE and
cholesterol/HDL ratio were significant in the linear regression
model. In females, results were slightly different, insofar that
only systolic blood pressure, plasma glucose, and cholesterol/
HDL ratio were associated with more renal function decline,
whereas triglycerides were found to be associated with less
renal function decline. In this model, inclusion of the
quadratic term of SBP was significant.
Figure 1 presents the graphical interpretation of the
associations between independent variables and eGFR slope
that were identified by multivariate regression analysis. More
renal function decline is observed in the higher range of
systolic blood pressure, glucose, and UAE, both in males and
in females. The curves for cholesterol/HDL ratio and waist
circumference versus change in eGFR over time, however,
show opposite patterns for males and females.
A priori-defined sensitivity analyses were performed. To
investigate whether inclusion of only subjects with reliable
slopes influences the results, we excluded the 773 males
and 812 females with observed eGFR values that were not
within the 99% confidence interval of the expected eGFR
value. The results obtained were only slightly different. In
males, the cholesterol/HDL ratio was not significantly
associated with change in renal function, whereas in females,
Table 1 | Baseline characteristics for the overall study population and for males and females separately
Overall (N=5488) Males (N=2770) Females (N=2718) P-value
Age (years) 49 (12) 50 (12) 48 (11) o0.001
Smoking (%) 34.5 34.3 34.7 NS
Positive family history (%) 31.3 31.1 31.4 0.003
Waist circumference (cm) 88.1 (12.7) 93.3 (10.8) 82.8 (12.3) o0.001
SBP (mm Hg) 128 (19) 133 (18) 123 (19) o0.001
Antihypertensive medication (%) 14.5 15.5 13.5 0.012
ACEi/A2A medication (%) 4.2 5.1 3.2 o0.001
Cholesterol/HDL ratio 4.6 (1.8) 5.2 (1.9) 4.0 (0.5) o0.001
Triglycerides (mmol/l)w 1.1 (0.8–1.7) 1.3 (0.9–1.9) 1.0 (0.8–1.5) o0.001
Lipid lowering medication (%) 6.2 7.0 5.4 o0.001
Glucose (mmol/l) 4.9 (1.2) 5.0 (1.3) 4.7 (1.0) o0.001
Antidiabetic medication (%) 1.3 1.4 1.2 NS
CRP (mg/l)w 1.20 (0.53–2.74) 1.16 (0.52–2.49) 1.24 (0.53–3.03) 0.001
UAE (mg/24 h)w 9.0 (6.2–15.3) 10.0 (6.8–18.8) 8.1 (5.8–12.9) o0.001
Urinary urea excretion (mmol/24 h) 361 (103) 397 (105) 324 (88) o0.001
Urinary sodium excretion (mmol/24 h) 143 (50) 159 (52) 127 (42) o0.001
eGFR (ml/min/1.73 m2) 80.7 (13.9) 83.8 (14.3) 77.5 (12.7) o0.001
ACEi, angiotensin converting enzyme inhibitors; A2A, angiotensin-II antagonists; CRP, hs C-reactive protein; eGFR, estimated glomerular filtration rate (MDRD); HDL, high-
density lipoprotein; SBP, systolic blood pressure; NS, not significant; UAE, urinary albumin excretion.
Values are given as mean (s.d.), or median (interquartile range) in case of skewed data (w) distribution. Statistical analyses, to test the differences between males and females,
were performed with t-test, Mann–Whitney test in case of skewed distribution, or w2 test in case of categorical variables.
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Table 2 | Univariate associations between baseline characteristics and change in renal function during follow-up (assessed as
slope through three eGFR values over time per individual)
Males (N=2770) Females (N=2718)
Standardized beta P-value Standardized beta P-value
Smoking 0.005 NS 0.003 NS
Positive family history 0.003 NS 0.010 NS
Waist circumference 0.052 0.006 0.023 NS
SBP 0.074 o0.001 0.046 0.016
Cholesterol/HDL ratio 0.069 o0.001 0.049 0.011
Ln_Triglycerides 0.054 0.005 0.015 NS
Glucose 0.135 o0.001 0.104 o0.001
Ln_CRP 0.026 NS 0.028 NS
Ln_UAE 0.126 o0.001 0.038 0.045
Urinary urea excretion 0.025 NS 0.025 NS
Urinary sodium excretion 0.021 NS 0.027 NS
CRP, hs C-reactive protein; eGFR, estimated glomerular filtration rate (MDRD); HDL, high density lipoprotein; NS, not significant; SBP, systolic blood pressure; UAE, urinary
albumin excretion.
In case of skewed distribution, data were Ln-transformed to obtain normal data distribution. A negative standardized beta indicates that the higher the value of the variable
under study, the more negative the slope of renal function over time is.
Table 3 | Associations between baseline characteristics and change in renal function during follow-up (assessed as slope
through three eGFR values over time per individual), with correction for baseline eGFR and age.
Male (N=2770) Female (N=2718)
Standardized beta P-value Standardized beta P-value
Smoking 0.027 NS 0.018 NS
Positive family history 0.005 NS 0.002 NS
Waist circumference 0.048 0.014 0.039 0.046
SBP 0.092 o0.001 0.074 o0.001
Cholesterol/HDL ratio 0.052 0.005 0.056 0.004
Ln_Triglycerides 0.029 NS 0.010 NS
Glucose 0.126 o0.001 0.094 o0.001
Ln_CRP 0.017 NS 0.038 0.041
Ln_UAE 0.145 o0.001 0.046 0.012
Urinary urea excretion 0.020 NS 0.026 NS
Urinary sodium excretion 0.022 NS 0.022 NS
CRP, hs C-reactive protein; eGFR, estimated glomerular filtration rate (MDRD); HDL, high density lipoprotein; NS, not significant; SBP, systolic blood pressure; UAE, urinary
albumin excretion.
In case of skewed distribution, data were Ln-transformed to obtain normal data distribution. A negative standardized beta indicates that the higher the value of the variable
under study, the more negative the slope of renal function over time.
Table 4 | Multivariate model for males explaining change in
renal function during follow-up (assessed as slope through
three eGFR values over time per individual)
Male (N=2770)
Standardized beta P-value
Ln_UAE2 0.581 o0.001
Cholesterol/HDL ratio2 0.129 o0.001
Waist circumference 0.102 o0.001
Glucose 0.096 o0.001
SBP 0.064 0.003
eGFR, estimated glomerular filtration rate (MDRD); HDL, high-density lipoprotein;
SBP, systolic blood pressure; UAE, urinary albumin excretion.
Variables included in the multivariate prediction model are statistically significant
associated with slope of renal function over time. The model is adjusted for baseline
eGFR, age, and the use of medication. In case quadratic terms of variables proved to
contribute significantly to the model (indicated with 2), the single term was also
forced into the model. For reasons of clarity, only results with respect to the quadratic
term are shown in the table. In case of skewed distribution, data were Ln-transformed
to obtain normal data distribution. A negative standardized beta indicates that the
higher the value of the variable under study, the more negative the slope of renal
function over time. The variables are ranked on the order of the standardized beta.
Table 5 | Multivariate model for females explaining change in
renal function during follow-up (assessed as slope through
three eGFR values over time per individual)
Female (N=2718)
Standardized beta P-value
SBP2 0.359 0.026
Glucose 0.067 0.002
Cholesterol/HDL ratio 0.061 0.014
Ln_Triglycerides 0.052 0.038
eGFR, estimated glomerular filtration rate (MDRD); HDL, high-density lipoprotein;
SBP, systolic blood pressure.
Variables included in the multivariate prediction model are statistically significant
associated with slope of renal function over time. The model is adjusted for baseline
eGFR, age, and the use of medication. In case, quadratic terms of variables proved to
contribute significantly to the model (indicated with 2), the single term was also
forced into the model. For reasons of clarity, only results with respect to the quadratic
term are shown in the table. In case of skewed distribution, data were Ln-transformed
to obtain normal data distribution. A negative standardized beta indicates that the
higher the value of the variable under study, the more negative the slope of renal
function over time. The variables are ranked in order of the standardized beta.
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only triglycerides were not found to be associated with
outcome anymore. The sensitivity analysis performed with a
mixed effects model with random intercepts and random
slopes resulted in models with the same variables included.
Additionally, we investigated the potential role of hormonal
status. For this purpose, we repeated the multivariate
linear regression analysis only in postmenopausal females
(N¼ 1107). Similar results were obtained as in the overall
group of females. Furthermore, we performed an analysis
using a relative instead of absolute measure for renal
function decline and an analysis using slopes through the
reciprocals of serum creatinine values as outcome variables.
The results of these analyses were essentially similar to
our primary analyses, as were the results of the analyses
performed in a subcohort representative for the general
population.
DISCUSSION
In this study, we investigated which modifiable risk factors
are associated with change in renal function during follow-up
in a community-based study cohort. We found different
results for males versus females. In males, UAE was the
strongest independent predictor of greater renal function
decline, together with plasma glucose and systolic blood
pressure. In contrast, waist circumference and cholesterol/
HDL ratio were associated with a better renal function
outcome. In females, systolic blood pressure and plasma
glucose were independent risk predictors of renal function
decline, whereas triglycerides were associated with better
renal prognosis.
The interest in identification of modifiable risk factors of
renal function decline is increasing. Such risk factors may be
used to estimate a subject’s risk of future renal function
decline and may also form the basis for preventive
intervention. The mean eGFR decline we found in this study
is low, probably not pathological and does not warrant
intervention. However, the goal of this study was to identify
predictors of accelerated renal function loss. Most obser-
vational studies investigating this issue apply ‘threshold’
analysis, using a cut-off value to indicate that subjects reach a
certain stage of CKD. Most common cut-off values are the
incidence of ESRD (defined as start of renal replacement
therapy) or de novo K/DOQI CKD stage 3 or 4 (defined as
eGFR below 60 or 30 ml/min/1.73 m2).9–12 This study applies
a ‘slope’ analysis. The choice of slope versus threshold
analysis has received scant attention, but has important
implications. This is illustrated by the following theoretical
example. It is known that in obese subjects GFR values
estimated with the modification of diet in renal disease
(MDRD) formula are considerably lower than their true GFR
because, in general, obesity is associated with more muscle
mass.13 Therefore, obese subjects at similar baseline true GFR
and at similar rate of true GFR loss as nonobese subjects will
reach an MDRD formula-based eGFR threshold of 30 or
60 ml/min/1.73 m2 earlier than their nonobese counterparts.
This suggests that obesity is a risk factor for renal function
decline, whereas a slope analysis would not have led to
this conclusion. One might consider that application of an
eGFR-independent threshold, such as the occurrence of
ESRD, might circumvent this problem. However, obesity has
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Figure 1 | Graphical representation of the association between
risk predictors and change in renal function during follow-up
(assessed as slope through three eGFR values over time per
individual). The Loess method (locally weighted polynomial
regression analysis)52 is used to plot these associations. Using this
method makes it possible to show a possible nonlinear
relationship, as the plots are ‘distribution free’. The histograms
(expressed as percentage) present the distributions of the
predictors. HDL, high-density lipoprotein; SBP, systolic blood
pressure; UAE, urinary albumin excretion.
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been found to be associated with better survival in subjects in
renal replacement therapy.14 In case this would also be true for
K/DOQI CKD stage 4, obese subjects would survive ‘prefer-
entially’. This will result in the observation that the proportion
of obese subjects that reaches ESRD is higher than in the
general population, again leading to the possible incorrect
conclusion that obesity is associated with worse renal function
outcome. For these reasons, together with the fact that we
wanted to study risk factors of renal function decline over the
entire eGFR range, we adopted a slope-based analysis with
change in renal function during follow-up as outcome
parameter. We also performed our analyses using slopes based
on the reciprocals of serum creatinine values and using relative
change in eGFR as outcome parameters. These analyses
resulted in the identification of the same predictors, making
our results convincing.
Applying a slope-based analysis, we found in both males
and females higher systolic blood pressure and higher plasma
glucose to be major determinants of change in renal function.
This is in line with other studies investigating community-
based populations, but applying threshold analysis. High
plasma glucose has been shown to be a risk factor of the
development of CKD15 and ESRD.16 The same holds true for
high blood pressure.12,17–19 Interestingly, similar to our study,
a study performed in Maryland, USA, showed in both males
and females a strong relationship between systolic blood
pressure and the development of CKD, with the relationship
being strongest in females and the cumulative incidence
of ESRD increasing exponentially in the more severe
stages of hypertension.20 Of note, we found a difference of
10 mmHg in systolic blood pressure levels between males and
females. This result is in line with other community-based
studies.21–24
We found UAE to be the best predictor of renal function
decline in males. This association was independent of the
effects of systolic blood pressure and plasma glucose.
Although most evidence on the impact of urinary albumin
leakage and renal prognosis is based upon data on overt
proteinuria in subjects with nondiabetic25,26 and diabetic27,28
renal disease, there is also evidence that lower amounts of
protein leakage predict renal function decline in the general
population. Iseki et al.29 showed that subjects with trace
dipstick-positive proteinuria already have an increased
incidence of ESRD during follow-up, as did the MRFIT
study.10 In a previous analysis, we found in the Prevention of
Renal and Vascular End-stage Disease (PREVEND) study
that, after 4.2 years of follow-up, subjects with microalbu-
minuria progress more frequently to an eGFR below a
threshold of 60 ml/min/1.73 m2 than subjects without
microalbuminuria.30 Remarkably, this study found that
UAE was not an independent predictor for renal function
decline in females. However, in females, the negative
association between UAE and renal function decline was
significant when tested univariately, and also when corrected
for baseline eGFR and age. We repeated our analyses using
the albumin/creatinine ratio with correction for age and
gender.31,32 The results of these analyses also showed that
albuminuria was an independent predictor for renal function
decline in males, but not in females. Most studies concerning
predictors of renal function decline do not report gender
differences in outcome. Possibly, this was not studied
specifically, and therefore gender differences may have
remained unnoticed. Furthermore, we should take into
account that we applied a slope-based analysis, in contrast
to other studies. Indeed, when we performed a threshold
analysis and investigated which subjects developed an eGFR
less than 60 ml/min/1.73 m2 during follow-up, we also found
no significant interaction between gender and UAE on
outcome (P¼ 0.53). However, our data on gender-specific
renal effects are in line with a previous report showing that
males have a higher UAE for a given age, plasma glucose, and
BMI than females.33
Another gender difference was observed with respect to
the impact of cholesterol/HDL ratio on change in renal
function. In females, a higher cholesterol/HDL ratio was
associated with more renal function decline, whereas we
found the opposite in males. Literature on cholesterol as an
independent predictor for renal function impairment is not
consistent, with some community-based studies finding total
cholesterol and/or triglycerides not to be an independent
predictor for the onset of CKD9 or ESRD,34 whereas others
found these variables to be associated with worse renal
outcome.34–36 A possible explanation for these inconsistent
results might be differences in length of follow-up, with
especially studies with longer follow-up suggesting that high
cholesterol and/or triglycerides influence renal function
outcome negatively.36,37
Surprisingly, we found that a greater waist circumference
was not associated with a worse renal prognosis. In fact, in
males, waist circumference was associated with a better renal
prognosis. Several other community-based studies reported
an association between a higher BMI and increased risk for
CKD.11,38,39 As mentioned before, these contradictory
findings might be due to the fact that in this study a slope-
based analysis is used, whereas other studies applied a
threshold analysis. When we analyzed which subjects
developed an eGFR less than 60 ml/min/1.73 m2 during
follow-up, we did not find a positive association between
waist circumference and change in renal function, neither in
the overall population, nor when we analyzed males
separately. Another explanation may again be duration of
follow-up. Data from the Okinawa screening project in Japan
showed that 10 years follow-up was not sufficient to establish
a relationship between BMI and the risk of developing
ESRD,40 whereas data of 17 years follow-up did show such an
association.38 Another study with longer duration of follow-
up (13.2 years) also showed an association between obesity
and renal prognosis.41 Thus, it could be that the follow-up of
6 years in our study is not sufficient to find a negative
association between waist circumference and renal function
decline. However, the fact that we found even a positive
association between waist circumference and change in renal
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function in males in our slope-based analyses is surprising,
and worth further study.
Strengths of this study are the use of a large prospective
community-based cohort, with three eGFR estimates avail-
able. Our study is one of the first studies that investigates risk
factors of renal function decline by a slope-based analysis. Of
course, also limitations should be kept in mind. First, the
relatively short follow-up in our study and the fact that there
are only three eGFR measurements available may have
influenced the precision of the calculated slope. Therefore,
we performed a sensitivity analysis, including only subjects
with ‘reliable’ slopes. This did not essentially affect our
results. Second, by using the calculated slope, we assume a
linear change in renal function over time. Although it is
generally used in nephrology, it is questionable whether this
assumption of linearity is correct. However, on these data
(three values available), it is appropriate to assume a linear
change.42 Third, our results may be biased by the influence of
loss to follow-up. Participants who died or were lost to
follow-up for other reasons may have been in a worse
condition of health. In general, such subjects have a higher
rate of renal function decline. Therefore, in our analyses, the
impact of risk factors may have been underestimated. To
investigate the potential bias induced by loss to follow-up, we
performed a mixed effects models analysis, which takes into
account also data available of subjects who attended only one
or two screenings. This again did not influence our main
conclusions. Fourth, we used the MDRD formula to estimate
the GFR. It is known that the use of the MDRD formula has
shortcomings.43,44 Estimating GFR with the MDRD formula
may introduce bias.45 As this bias is systematic, that is,
constant in a particular subject, this bias is expected not to
influence our analyses, as we use change in eGFR as outcome
parameter, and not the absolute value of eGFR. In addition,
at this moment, there is no other feasible method to estimate
GFR, and the MDRD-based GFR estimates are easy to
interpret for clinicians. Fifth, we studied a relatively healthy
Caucasian population. Our findings may therefore not be
valid for other populations.
In conclusion, this community-based observational po-
pulation study investigated which modifiable variables were
associated with change in renal function during follow-up,
applying a slope-based analysis. Results differed between
males and females. High systolic blood pressure and plasma
glucose were found to be independent predictors for worse
renal outcome in both males and females. In males, UAE was
identified as the strongest independent predictor for renal
function decline. In females, UAE was only univariately, and
after adjustment for age, associated with change in renal
function. The direction of the association between cholester-
ol/HDL ratio and change in renal function was different in
males and females. In males, predictors independently
associated with a better renal function outcome were waist
circumference and cholesterol/HDL ratio, whereas in females
this was higher triglycerides. Our findings suggest that, in
future studies, possible gender-specific risk predictors for
renal function decline should be taken into account.
Furthermore, these data may help to make renal risk
prediction scores to identify subjects in the general popula-
tion at risk of renal function decline, who may benefit from
early preventive intervention.
MATERIALS AND METHODS
Study design and population
The analyses are based on data of subjects who participated in
the first three screening rounds of the PREVEND study. This
is a prospective cohort study, designed to investigate the impact
of UAE on renal and cardiovascular outcome in the general
population. In 1997–1998, the participants of the PREVEND
cohort were selected from 40,856 inhabitants of the city of
Groningen, the Netherlands. Selection was based on the albumin
concentration in a spot morning urine sample to obtain a cohort
enriched for the presence of elevated albuminuria levels. At
approximately 3-year intervals, participants in this study are invited
to visit an outpatient department for measurements concerning
their health status. Details of the study protocol have been published
elsewhere.46,47
In total, 8592 participants completed the first screening round
in 1997–1998. Approximately 6.5 years later, from 2003 to 2006,
the third screening round took place. During the interval between
the first and the third screening round, 377 subjects died and
2415 patients were lost to follow-up, however, with vital status
known (Figure 2). Thus, 5862 subjects completed the third screen-
ing round. For this study, we excluded subjects who indicated
in a questionnaire to have a renal disease during the first screening
round (n¼ 22). Subjects with missing information on eGFR in one
of the three screening rounds were also excluded (n¼ 352), leaving
5488 subjects for analysis. The PREVEND study was approved by
the local medical ethics committee and conducted in accordance
with the Declaration of Helsinki Principles. All participants gave
written informed consent.
Measurements and definitions
Each screening round consisted of two visits to an outpatient
department separated by approximately 3 weeks. Participants filled
8592
First screening, 1997–1998
6894
Second screening, 2001–2003
5862
Third screening, 2003 –2006
240
Died
1458
Withdrawals
957
Withdrawals
75
Died
62
Died
2.2 year FU
4.2 year FU
Figure 2 | Flowchart of the PREVEND study.
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out a questionnaire on demographics, cardiovascular and renal
history, smoking status, menstrual status, and the use of oral
antidiabetic, antihypertensive, and lipid-lowering drugs. A positive
family history of cardiovascular disease was defined as having a first-
degree family member who experienced a cerebrovascular accident,
myocardial infarction, or intervention for peripheral vascular disease
before the age of 65 years. Postmenopausal status for females was
defined as the absence of menstruation for at least 6 months before
the first screening. Smoking was defined as current smoking, or
cessation of smoking less than a year before the baseline screening.
Information on drug use was completed with data from community
pharmacies. During both study visits per screening round, blood
pressure was measured in the right arm, every minute for 10 and
8 min, respectively, by an automatic Dinamap XL Model 9300 series
device (Johnson-Johnson Medical INC, Tampa, FL, USA). For
systolic blood pressure, the mean of the last two recordings from
each of the two visits was used. Anthropometrical measurements
were performed, and fasting blood samples were taken. In addition,
subjects collected urine for two consecutive periods of 24 h.
Concentrations of total cholesterol, HDL-cholesterol, triglycerides,
glucose, C-reactive protein, and urinary urea and sodium were
measured using standard methods. Serum creatinine was measured
by dry chemistry (Eastman Kodak, Rochester, NY, USA), with intra-
and interassay coefficients of variation of 0.9 and 2.9%, respectively.
Urinary albumin concentration was determined by nephelometry
(Dade Behring Diagnostic, Marburg, Germany), and UAE was given
as the mean of the two 24 h urinary excretions. eGFR was estimated
using the MDRD study equation, taking into account gender, age,
race, and serum creatinine.48
Statistical analyses
Baseline characteristics of subjects included in this analysis are given
in Table 1. Continuous data are reported as the mean and standard
deviation. For skewed distributions, the median and interquartile
range are presented. To identify risk factors of renal function decline,
we performed linear regression analyses. For all our regression
models, we used change in eGFR over time as outcome variable.
This variable was defined for each subject as the slope of the linear
regression line through their three eGFR measurements that were
obtained at the consecutive screening rounds in the PREVEND
study. As possible predictors of renal function decline, all variables
tested are enlisted in Table 1, as these have all been suggested to
influence renal outcome in patients with known renal disease. When
necessary, these variables were Ln-transformed to obtain normal
data distribution. First, we performed univariate regression analysis.
Second, we repeated this analysis, with correction for age and
gender, as these factors are nonmodifiable. We also corrected for
baseline eGFR to reduce the effect of regression to the mean. Third,
we performed forward multivariate regression analysis. A P-value of
0.05 was adopted as the entry criterion for including variables in the
regression model. Because of the reasons described above, gender,
age, and baseline eGFR were forced in the model. As the use of
medication interfering with the variables under study (for example,
antihypertensives) may influence results, we corrected the multi-
variate models (Tables 4 and 5) for the use of medication. All
variables under study were tested for possible nonlinear associations
by adding quadratic terms to the multivariate regression model and
to test their inclusion for statistical significance. Furthermore, we
explored possible effect modification by implementing interaction
terms, for all variables that significantly contributed to the
multivariate regression model in the model. It was a priori decided
that, in case a significant interaction was to be found, all models
were to be built taking into account this interaction. Lastly,
graphical representations were made of the final models, showing
the relation between the most important predictors and the change
in renal function. For this analysis, the mean slope of renal function
over time was calculated per quintile of each predicting variable.
All analyses were conducted with the statistical package SPSS
14.0 (SPSS, Chicago, IL, USA). A P-value of 0.05 or less was adopted
to indicate statistical significance.
Sensitivity analyses
Various sensitivity analyses were performed. First, we performed a
sensitivity analysis including only subjects in whom a ‘reliable’ slope
of renal function over time could be calculated. To judge slopes as
reliable, we calculated the theoretical 99% confidence interval of the
expected eGFR value for every observed eGFR measurement. This
confidence interval is determined by intrapatient day-to-day
coefficient of variation (CV) in true GFR, and by measurement
error in serum creatinine. The CV in true GFR and creatinine
measurement in our institution has previously been shown to be
2.2 and 1.1%, respectively.49,50 The overall CV for the expected GFR
can be calculated according to the formula O((CV true GFR)2þ
(CV creatinine)2) and the 99% confidence interval. In case all three
observed eGFR values of a subject were within the calculated 99%
confidence intervals of the expected eGFR values, we defined the
slope as reliable (males n¼ 2007, females n¼ 1911). Second, we
performed sensitivity analyses to test whether loss to follow-up
influenced results. For this reason, we repeated our analyses using a
mixed effects model with random intercepts and random slopes.
Such a model estimates the rate of change in eGFR over time,
including also subjects with only one or two eGFR measurements.42
Third, we repeated our analyses using the following outcomes:
(a) percentage change in eGFR and (b) slopes through the
reciprocals of serum creatinine. Fourth, to investigate whether the
enrichment for albuminuria in our cohort influenced the results,
we performed our analyses in a subcohort representative for the
general population (N¼ 2269). A detailed description how this
cohort was formed has been published previously.51
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